No actions available.
Full Text of this Amendment
At the appropriate place, insert the following:
SEC. __. PROHIBITION OF REORGANIZATION PLAN PENDING REVIEW.
(a) In General.--The Commissioner of Food and Drugs may not implement a reorganization plan that reduces or consolidates the number of laboratory facilities currently in operation within the Office of Regulatory Affairs of the Food and Drug Administration pending a comprehensive review of the reorganization plan by the Comptroller General of the United States to determine--
(1) the impact of the reorganization on the mission of the Food and Drug Administration to ensure that foods, cosmetics, and medical products are safe, effective, and properly promoted and labeled;
(2) the projected cost savings; and
(3) the projected operational efficiencies.
(b) Report.--Not later than 1 year after the date of enactment of this section, the Comptroller General of the United States shall issue a report on the impact of the reorganization plan described in subsection (a).
(As printed in the Congressional Record for the Senate on May 2, 2007.)